Abstract
ATTRACTION-2 trial showed that nivolumab significantly prolonged overall survival compared with Best Supportive Care, with a median overall survival of 5.26 months. We report a case of gastric cancer with peritoneal dissemination that has achieved long-term survival of 2 years or more after administration of nivolumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
